Mariner LLC Boosts Stock Position in Stryker Co. (NYSE:SYK)

Mariner LLC increased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 4.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 571,002 shares of the medical technology company's stock after acquiring an additional 26,691 shares during the period. Mariner LLC owned about 0.15% of Stryker worth $205,597,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. SageView Advisory Group LLC boosted its holdings in Stryker by 45.6% in the fourth quarter. SageView Advisory Group LLC now owns 1,573 shares of the medical technology company's stock valued at $566,000 after acquiring an additional 493 shares during the last quarter. Savvy Advisors Inc. boosted its holdings in shares of Stryker by 18.4% during the fourth quarter. Savvy Advisors Inc. now owns 1,644 shares of the medical technology company's stock worth $592,000 after acquiring an additional 256 shares during the period. Bragg Financial Advisors Inc raised its position in shares of Stryker by 151.2% in the 4th quarter. Bragg Financial Advisors Inc now owns 10,031 shares of the medical technology company's stock valued at $3,612,000 after buying an additional 6,038 shares in the last quarter. BTG Pactual Asset Management US LLC boosted its holdings in shares of Stryker by 18.8% in the 4th quarter. BTG Pactual Asset Management US LLC now owns 5,535 shares of the medical technology company's stock valued at $1,993,000 after purchasing an additional 877 shares in the last quarter. Finally, Granite Investment Partners LLC boosted its stake in Stryker by 31.3% in the fourth quarter. Granite Investment Partners LLC now owns 60,616 shares of the medical technology company's stock valued at $21,825,000 after buying an additional 14,461 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Down 0.1 %

Shares of NYSE SYK traded down $0.21 during midday trading on Friday, hitting $346.46. 1,349,873 shares of the company traded hands, compared to its average volume of 1,362,954. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The stock has a 50-day moving average price of $371.83 and a 200 day moving average price of $373.11. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market cap of $132.24 billion, a P/E ratio of 44.65, a P/E/G ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business earned $3.46 earnings per share. As a group, analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SYK. Royal Bank of Canada raised their target price on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. JMP Securities reissued a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Citigroup reaffirmed a "buy" rating and set a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Canaccord Genuity Group raised their price objective on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. increased their target price on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $423.53.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.